Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Topsiders Must Testify In Plan B Case – Judge

This article was originally published in The Tan Sheet

Executive Summary

The Center for Reproductive Rights will be allowed to take depositions from certain FDA "senior decision-makers" in their suit against the agency over decisions related to emergency contraceptive Plan B
Advertisement

Related Content

FDA Depositions Reveal Crawford’s Prominent Role In Plan B Switch Review
FDA Must Take Action On Omnitrope Review, Court Says; Will Plan B Follow?
Wisconsin “Lacks Standing” To Become Plaintiff In Plan B Lawsuit – FDA
Wisconsin Looks To Join Plan B Lawsuit Plaintiffs
“New” Plan B Emails Say FDA’s “Novel” Concerns Were Not Novel – Waxman
FDA Disagrees With GAO’s “Unusual” Findings Regarding Plan B Decision
FDA “Unable” To Decide On Plan B, Seeks Comment On Dual-Status Drugs
FDA Memo Sheds Light On Plan B Discussions
FDA Memo Sheds Light On Plan B Discussions
Plan B OTC Submission Fails On Lack Of Data In Teens

Topics

Advertisement
UsernamePublicRestriction

Register

PS099152

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel